Get Help Sign In

Alt-R™ CRISPR Custom Guide RNAs

Guide RNAs for novel Cas enzymes (e.g., prime editing or the Cas13 family)

Our well-established expertise in oligo synthesis combined with an active CRISPR research and development program are what make us a trusted vendor for custom gRNA synthesis.

  • Fast shipping (usually 3–5 business days)
  • A range of purification and modification options
  • Multi-scale delivery in tubes or plates

We also offer a complete selection of Cas9 guide RNAs (sgRNA, crRNA, and tracrRNA) as well as Cas12a guide RNAs.


CRISPR Custom Guide RNAs

We offer chemically synthesized and modified custom guide RNAs for common as well as exotic research applications. Alt-R Custom Guide RNAs are ideal for prime editing (pegRNA) projects, CRISPR-Cas13 applications, and most alternative CRISPR-Cas systems.

All our CRISPR guide RNAs are available with chemical modifications that increase stability, potency, and/or nuclease resistance. Some modifications can decrease unwanted immune responses in your experiments.


Incredible flexibility to meet a wide range of guide RNA needs.

Alt -R CRISPR Custom Guide RNAs are chemically synthesized and modified. These guide RNAs include pegRNA for the prime editing system as well as guide RNAs for the Cas13 family of enzymes and other unusual Cas systems.

Prime editing guide RNA (pegRNA)

The laboratory of David Liu (Broad Institute of MIT and Harvard, Cambridge, MA) has published a CRISPR genome editing technique called prime editing (Anzalone et al., 2019). This involves a Cas9 H840A nickase fused to a reverse transcriptase, in combination with a long guide RNA (prime editing guide RNA or pegRNA). The pegRNA encodes the new sequence and allows transcription to introduce the desired mutations. This system may have great promise for the development of treatments for genetic diseases. It is an exciting complement to existing CRISPR editing systems and may even be an improvement in many cases.

Cas13 guide RNA

The CRISPR-Cas13 family of enzymes targets and cuts RNA instead of DNA. Papers from the Feng Zhang lab at the Broad Institute and the Stanley Qi lab at Stanford University demonstrate the potential of CRISPR-Cas13 for SARS-CoV-2 detection as well as the development of COVID-19 therapies.

Brochures and flyers

Frequently asked questions